Posdinemab (JNJ-63733657) 是一种选择性靶向磷酸化 tau (pT217) 的人源化 IgG1/κ 单克隆抗体。Posdinemab 特异性结合富含脯氨酸结构域的 pT217+tau 表位,阻断 tau 蛋白聚集及种子传播,促进细胞外 tau 物种的清除。Posdinemab 减少脑脊液中游离和总 p217+tau 水平,从而抑制 tau 蛋白的病理传播和神经纤维缠结形成。Posdinemab 可用于进行性核上性麻痹综合征和阿尔茨海默症 (AD) 研究,尤其针对前驱期或轻度 AD 疾病。
Posdinemab (JNJ-63733657) is a humanized IgG1/κ monoclonal antibody that selectively targets phosphorylated tau (pT217). Posdinemab specifically binds to the pT217+tau epitope rich in the proline domain, blocks tau protein aggregation and seed propagation, and promotes the clearance of extracellular tau species. Posdinemab reduces the levels of free and total p217+tau in cerebrospinal fluid, thereby inhibiting the pathological propagation of tau protein and the formation of neurofibrillary tangles. Posdinemab can be used for the study of progressive supranuclear palsy syndrome and Alzheimer's disease (AD), especially for prodromal or mild AD disease.